News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GeneThera, Inc. (GTHA.OB) Will Test Milk and Dairy Products Due to Evidence Linking Johne's Disease to Irritable Bowel Syndrome (IBS) and Crohn's Disease



12/22/2008 9:09:34 AM

WHEAT RIDGE, CO--(Marketwire - December 19, 2008) - GeneThera, Inc. (PINKSHEETS: GTHR) announced it will begin testing of raw and processed milk and dairy products using its Real Time PCR test for Johne's disease through its Wheat Ridge, CO laboratory.

GeneThera is set to begin offering its Johne's disease testing service as soon as January of 2009 and says it will add testing of milk and other dairy products due to the overwhelming evidence linking Johne's disease in cattle to Irritable Bowel Syndrome (IBS) and Crohn's disease in humans.

According to GeneThera Chairman, Dr. Tony Milici, MD, PhD, "GeneThera specializes in diagnostic assays and vaccines for what we call 'Crossover Diseases.' These are diseases that are typically found in cattle, but create a significant risk to humans that consume them. Some other examples would be E. coli, and Bovine Spongiform Encephalopathy, otherwise known as Mad Cow Disease. We feel that not enough is being done by the USDA to properly protect the American consumer from these harmful pathogens."

According to the VA Medical Center in Bronx, NY, "... Although Crohn's disease is considered to be autoimmune in origin; there is increasing evidence that it may have an infectious cause. The most plausible candidate is Mycobacterium avium subspecies paratuberculosis (MAP)."

In an article reviewed by About.com's Medical Review Board titled "Know What's In Your Milk?," it is reported that the bacteria causing Johne's is shed by the infected cow into her milk. The current pasteurization method is based on High Temperature, Short Time (HTST). This means that the milk is heated to 72 degrees Celsius (162 degrees F) for 15 seconds. The time period of 15 seconds has been shown to be insufficient to kill all of the paratuberculosis bacteria. As a result, paratuberculosis could live through the pasteurization process and be in cartons of milk on grocery store shelves. In fact, researchers found that up to 25% of milk on store shelves in central and southern England contained paratuberculosis DNA.

A paper published by the Journal of Clinical Microbiology in December 2007 stated, "... Mucosal biopsy specimens from the ileum and the ascending and descending colon were obtained from patients with irritable bowel syndrome attending the University of Sassari, Sassari, Sardinia, Italy. Crohn's disease and healthy control groups were also included. Mycobacterium avium subsp. paratuberculosis was detected in 15 of 20 (75%) patients with irritable bowel syndrome, 3 of 20 (15%) healthy controls, and 20 of 23 (87%) people with Crohn's disease." The paper concluded by saying, "Mycobacterium avium subsp. paratuberculosis is a candidate pathogen in the causation of a proportion of cases of irritable bowel syndrome as well as in Crohn's disease."

Currently, there are no regulations requiring the disposal of milk found to contain Mycobacterium Paratuberculosis. If milk tested on the farm or at a processing plant is found to contain the bacteria, it is still processed and delivered to stores.

The company states that its Real Time PCR test is much more accurate and timely than what is commonly available today and results are typically available within 24-48 hours of receipt of the samples.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.


Dr. Tony Milici
303-463-6371

Goldsmith Group
303-838-4370

JR Dopkin & Associates
516-884-3200


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES